+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Minutes +
All Genders
ID06031688

Randomized Study of Tepotinib With or Without Ramucirumab for Advanced MET Exon 14 Skipping Non-Small Cell Lung Cancer

Led by SWOG Cancer Research Network · Updated on 2026-10-09

56

Participants Needed

278

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating treatments for advanced or recurrent non-small cell lung cancer NSCLC with a specific MET exon 14 skipping gene mutation. This phase II trial compares the effects of the drug tepotinib alone versus tepotinib combined with ramucirumab. Tepotinib is a kinase inhibitor that blocks abnormal MET protein signals to slow tumor growth, while ramucirumab is an antibody that may prevent tumor blood vessel growth. Patients are randomly assigned to one of two groups one receives ramucirumab intravenously on day 1 of each 21-day cycle plus daily oral tepotinib for 21 days the other receives only daily oral tepotinib for 21 days per cycle. Treatment cycles continue unless the disease worsens or side effects become unacceptable. Optional scans and sample collections occur before and during treatment, including lymphoscintigraphy, blood and urine tests, CT scans, and MRI. Participants undergo regular assessments throughout the trial, including imaging and laboratory tests to monitor tumor response and side effects. After treatment ends, follow-up visits occur every 12 weeks until disease progression, then every 6 months for 2 years, and a final check at 3 years from randomization. Researchers measure response rates, progression-free survival, overall survival, treatment-related side effects, and duration of response.

CONDITIONS

Brief Title

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here